MedTrace Logo

A Comparative Bioavailability Study of Two Torasemide 10 mg Tablets Formulations in Healthy Adult Participants Under Fasting Conditions:

NCT07201584 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2026-01-14

No results posted yet for this study

Summary

The purpose of this study is to evaluate the bioavailability, safety and tolerability of Torasemide 10 mg tablets (Berlin-Chemie AG), compared to Unat® 10 tablets (Viatris Healthcare GmbH) in healthy adult participants under fasting conditions.

Conditions

  • Healthy Adult Male and Female Volunteers

Interventions

DRUG

Torasemide tablet 10 mg

Tablets by Berlin-Chemie AG (Germany)

DRUG

Unat® 10 tablets (Torasemide 10 mg)

Tablets by Viatris Healthcare GmbH (Germany)

Sponsors & Collaborators

  • Berlin-Chemie AG Menarini Group

    lead INDUSTRY

Principal Investigators

  • Guldana Abdullaeva, MD · LLP MedStartUp, Ili district, Otegen Batyr settlement, Industrial Zone 200A, Almaty region

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-09-05
Primary Completion
2025-12-30
Completion
2026-04-01

Countries

  • Kazakhstan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07201584 on ClinicalTrials.gov